31504-19-5Relevant articles and documents
METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
-
Page/Page column 26, (2008/12/07)
The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit incl
METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
-
Page/Page column 79, (2010/11/24)
The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
Conformational restraint is a critical determinant of unnatural nucleotide recognition by protein kinases
Ulrich, Scott M,Sallee, Nathan A,Shokat, Kevan M
, p. 3223 - 3227 (2007/10/03)
This report describes the synthesis of N4-(benzyl) AICAR triphosphate, a conformationally restrained analogue of N4-(benzyl) ribavirin triphosphate. Both of these nucleotides were evaluated as phosphodonors for wild-type p38 MAP kina